Chum salmon (Oncorhynchus keta) nasal cartilage was examined by next-generation DNA sequencing and mass spectrometric analyses, and 14 types of proteoglycans including epiphycan (EPY) were found. A cDNA encoding EPY was cloned and sequenced. The cDNA encoded 589 amino acids comprised a glycosaminoglycan (GAG) domain containing 55 potential GAG-modified sites (SerGly and/or Gly-Ser), a cysteine cluster and 6 leucine-rich repeats. EPY was purified from salmon nasal cartilage and the structure of the GAG was characterized. As a result of unsaturated disaccharide analysis, GAG was found to be composed of chondroitin 6-sulfate (58.0%), chondroitin 4-sulfate (26.5%) and non-sulfated chondroitin (15.3%). The average molecular weight of GAG was estimated to be 3.0 × 10 4 . Ser-100 and Ser-103 were identified as serine residues substituted by GAG chains by chemical modification and mass spectrometric analysis. More than 50 serine residues were assumed to be substituted by GAG chains. EPY is heavily substituted by chondroitin sulfate, giving an overall molecular weight of just under 2 × 10 6 . EPY from salmon nasal cartilage is a novel type of large leucine-rich proteoglycan.
Introduction
Proteoglycan is composed of glycosaminoglycan (GAG) and a core protein (Hassell et al. 1986 ). GAG chains are usually covalently bound through O-glycosidic linkages to serine residues in the proteoglycan core protein. In extracellular matrices of all tissues, proteoglycans exist as structural variants, further increasing their functional and structural diversity. Some proteoglycans, such as aggrecan, decorin and biglycan, are expressed in cartilage and are thought to play important roles in chondrogenesis and cartilage formation (Knudson and Knudson 2001) , whereas others, such as neurocan, versican and N-syndecan, are expressed in nervous system and play important roles in neural development (Bandtlow and Zimmermann 2000; Bovolenta and Fernaud-Espinosa 2000) .
Aggrecan and epiphycan (EPY, also named DSPG3 or PG-Lb) were previously found in salmon nasal cartilage (Kakizaki et al. 2011) . Aggrecan from salmon nasal cartilage is characterized as a core protein of 1324 amino acids ( predicted molecular weight of 143,276), and 46 serine residues are substituted by GAG. The functional globular domains (G1, G2 and G3 domains) in the core protein are conserved between salmon and mammal. EPY is a member of small leucine-rich repeat proteoglycan (SLRP) family 3 and includes dermatan sulfate/ chondroitin sulfate (DS/ChS) and a core protein of molecular weight 4.3 × 10 4 in chick epiphyseal cartilage (Shinomura et al. 1983; Shinomura and Kimata 1992) . EPY is exclusively expressed in the developing epiphyseal cartilage during skeletal maturation in chicken (Kurita et al. 1996) , human (Deere et al. 1996) , bovine (Johnson et al. 1997) , mouse (Iwata et al. 1998) and zebrafish (Zhou et al. 2006 ) and had never previously been found in nasal cartilage. It is assumed that the structure and the function of EPY in salmon nasal cartilage are likely to be different from EPY found in epiphyseal cartilage. The structure and the role of this EPY in salmon nasal cartilage are unclear. Therefore, this study investigated the structure of EPY using nanoflow-linear quadrupole time-of-flight tandem mass spectrometer (nano-LC/MS/MS) and next-generation DNA sequencing techniques. Moreover, EPY was purified from salmon nasal cartilage and then examined for its unique structure.
Results

Identification of proteins by nano-LC/MS/MS
The tryptic fragments of the proteoglycan fraction from salmon nasal cartilage were analyzed by nano-LC/MS/MS. A total of 14,475 MS/MS spectra were acquired and then applied to the non-redundant NCBI database with a taxonomy restriction confined to Actinopterygii proteins. Results from the database search are constrained to proteoglycans as shown in Table I . The results showed that six proteoglycans were matched with a ProteinPilot confidence score >1.3 (95% confidence level). The identified proteoglycans included aggrecan, decorin, biglycan, EPY, prolargin and perlecan. Aggrecan (accession number: BAJ61837) was identified with the highest score (71.82) and sequence coverage (35.88%) because the amino acid sequence of Oncorhynchus keta aggrecan was given and aggrecan was the major proteoglycan in salmon nasal cartilage (Kakizaki et al. 2011) . The identified SLRPs were decorin (NP_001167033, accession number is in parentheses), biglycan (ACO59961), EPY (CAP08006) and prolargin (XP_001923590) with a confidence score of 6.15, 6.00, 4.14 and 2.43, respectively. Basement membrane-specific heparan sulfate (HS) proteoglycan, perlecan (XP_003201256), was also identified with a low score of 2.09. These proteoglycans, except for aggrecan, were identified as the orthologs of Salmo salar and Danio rerio, because the O. keta genes were not available. Identified collagens and extracellular matrix proteins by nano-LC/MC/MC were listed in Supplementary data, Table S1 .
Next-generation sequencing of salmon nasal cartilage cDNA The cDNA library was constructed from a pool of mRNA isolated from a nasal cartilage of O. keta and was sequenced using the 454 GS FLX platform and Titanium reagents. After the initial quality filtering, the sequencing run produced 39,585 reads with an average length of 313 bp and a total length of 12,386,290 bases. The raw sequence data from the next-generation sequence analysis has been deposited in the DNA Data Bank of Japan (DDBJ) Sequence Read Archive (DRA) with accession DRA001005. The assembly of the sequence reads was composed of 8119 unique sequences (3579 contigs and 4540 singletons). Proteoglycans were extracted from the results of a BLAST search of the unique sequences, which are shown in Table II . In all, 14 proteoglycans were identified with the expectation value (E-value) of <10 −20
. The Contig-2043 sequence was matched to O. keta aggrecan with an E-value and a score of 1.18 × 10 −163 and 494, respectively. Oncorhynchus mykiss decorin was identified with the highest score of 698 bits. The other SLRPs (biglycan, EPY, mimecan, lumican, fibromodulin 1b, podocan and prolargin) were also identified with a high score. ChS proteoglycan 4, glypican 4, leprecan 1, perlecan, and syndecan 2 were identified with a relatively low score. The count of the sequences matched with aggrecan (AB571294), biglycan (NM_001001825), decorin (NM_001173562) and EPY (NM_001017903) were 161, 60, 804 and 311 per 39,585 reads, respectively. These counts could not be standardized to calculate RPKM (reads per kilobase of exon model per million mapped reads), because the full-length sequences of the proteoglycans from O. keta, except for aggrecan, were not available. Identified collagens and extracellular matrix proteins by cDNA analysis using next-generation sequencing and PSI-BLAST program were listed in Supplementary data, Table S2 .
Primary structure of O. keta EPY The complete coding sequence for the EPY gene was cloned by reverse transcriptase-polymerase chain reaction (PCR). The cDNA comprising 1972 nucleotides was sequenced. The nucleotide sequence has been deposited in the DDBJ database with accession number AB762418. The predicted protein product was 589 amino acids in length with a calculated molecular weight of 59,347 (Figure 1 ). The N-terminal 384 amino acids encode a novel sequence. The sequence comprised a GAG domain containing a large proportion of Ser-Gly and/or Gly-Ser dipeptides (55 sites). Moreover, these dipeptides were separated by acidic and hydrophobic amino acid residues. The GAG domain shared no sequence homology with any proteins in the NCBI database (Supplementary data, Figure S1 ). The EPY core protein also included the domain structure of a cysteine cluster (CX 2 CXCX 6 C), which is characteristic of class III SLRPs, and six LRR consensus sequences LX 2 LXLX 2 NXL in the Figure S1 ).
Purification of EPY
Proteoglycans were extracted from salmon nasal cartilage slices according to the standard procedure using 4 M guanidine-HCl (Malawista and Schubert 1958; Hascall and Sajdera 1969; Sajdera and Hascall 1969) . EPY was prepared from the extracted proteoglycan fraction by DEAE-Sephacel chromatography, gel filtration chromatography on a Sepharose CL-4B column in 4 M guanidine-HCl, and hydrophobic interaction chromatography on Octyl-Sepharose using a 2-6 M guanidine-HCl linear gradient.
The chromatogram in Figure 2 shows the elution profile of proteoglycans from the DEAE-Sepharose column using a 0-1 M NaCl linear gradient. A large peak that eluted at a NaCl concentration of 0.3-0.6 M (fraction numbers 72-91) was enriched in uronic acid. This component was purified further by gel filtration chromatography on a Sepharose CL-4B column (Figure 3 ). The uronic acid-containing fractions were eluted as a single peak in the area with K av ranging from 0 to 0.3. These fractions contained EPY and aggrecan as detected by dot blot analysis using anti-DSPG3 and anti-aggrecan G3 domain antibodies. It is worth noting that the elution of EPY overlaps with aggrecan, suggesting similarity in the molecular weight of EPY and aggrecan. The fractions (elution volume of 71-135 mL) were pooled and purified further by hydrophobic interaction chromatography. The EPY-containing fractions from the gel filtration chromatography were applied to an Octyl-Sepharose column. The bound A novel type of large leucine-rich proteoglycan proteoglycans were subsequently eluted with a linear gradient of increasing guanidine-HCl concentration. Fractions were analyzed for EPY content by dot blot analysis, which revealed the presence of a major peak (fraction numbers 41-52, Figure 4A ). The fractions were also analyzed by dot blot analysis using an antibody against the aggrecan G3 domain to test whether the fractions were contaminated with aggrecan. As the result of the dot blot analysis, aggrecan was detected in flow-through fraction (fraction numbers 10-22, Figure 4A ) and showed peak tailing through the later fractions. Therefore, the fractions containing EPY were contaminated with a small amount of aggrecan. Fractions (fraction numbers 41-52, Figure 4A ) that included a mixture of EPY and aggrecan were reapplied to an OctylSepharose column to facilitate the separation of the two proteoglycans. The fractions eluted with increasing guanidine-HCl concentration were analyzed for EPY and aggrecan by dot blot analysis and showed that EPY-containing fractions (fraction numbers 16-20, Figure 4B ) were separated from aggrecan fractions. The purified EPY included 2.7 mg uronic acid per 1 mg of core protein. The purified EPY was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (4-20% acrylamide gradient gel). No distinct bands were observed on the gel stained with Coomassie Brilliant Blue (data not shown). The samples did not seem to migrate into the gel, because a smear was observed at the origin of the gel after alcian blue staining. EPY was purified from the guanidine-HCl extract of salmon nasal cartilage in 1% yield and was pooled for further studies.
GAG structure
The isolated EPY was subjected to protease degradation, and the GAG chains were trimmed by endo-β-xylosidase activity of cellulase from Aspergillus niger (Takagaki et al. 2002) . The GAG chains were isolated by chromatography on DEAE-Sepharose. The GAG chains were applied to gel-filtration high performance liquid chromatography (HPLC) using an OHpak SB-805HQ column. The average molecular weight of GAG was estimated to be 3.0 × 10 4
, and the distribution of the molecular weight ranged from 1.8 × 10 4 to 7.0 × 10 4 ( Figure 5 ). The later two peaks (elution volume at 11.5 and 12.2 mL) were not sugar chains, because they were detected in a negative control (GAG-minus). Therefore, the GAG fraction included no contaminating saccharide. Figure 6 shows the electrophoretic profile of GAG from EPY on the cellulose acetate membrane (lane 3). The migration of the major band was identical to that of chondroitin 4-sulfate (Ch4S) and chondroitin 6-sulfate (Ch6S) standard, suggesting that the GAG chain was ChS. A weak smeary band was observed at an intermediate position between the migration of the standard DS and ChS. Electrophoretic migration depends on the net negative charge of sample molecules in the buffer system used. Thus, the minor band of GAG was assumed to be ChS or DS bearing weaker or stronger negative charge due to the degree of sulfation, respectively. The digests of GAG by chondroitinase ABC, AC-II and B were analyzed by cellulose acetate membrane electrophoresis ( Figure 6 , lanes 4-6, respectively). The GAG was completely degraded by chondroitinase ABC and AC-II ( Figure 6 , lanes 4 and 5), whereas chondroitinase B had little effect on GAG ( Figure 6 , lane 6). These observations indicate that GAG in EPY is ChS.
The chemical composition of GAG was examined by analysis of unsaturated disaccharides. Figure 7 shows the distribution of unsaturated disaccharides from GAG (derived from EPY). The unsaturated disaccharides from GAG by chondroitinase ABC digestion included Ch6S units (58.0% ΔDi-6S) and Ch4S units (26.5% ΔDi-4S) as the major components and small amounts of non-sulfated chondroitin units (15.3% ΔDi-0S). Although the total unsaturated disaccharides decreased when GAG was digested by chondroitinase AC-II, the percentage distributions were similar to those of the chondroitinase ABC digest ( Figure 7B ). GAG was slightly degraded by chondroitinase B ( Figure 7C ). Although the partial resistance to chondroitinase AC-II digestion and a little sensitivity to chondroitinase B implied the existence of the ChS/DS hybrid chain, DS is considered to be a trace component. So the major component of GAG in EPY is suggested to be the ChS chain.
Identification of a serine residue modified by GAG Chemical modification and mass spectrometric analysis were applied to EPY for the identification of the sites modified by GAG chains. GAG chains are attached to proteoglycan via alkali-sensitive linkages. Alkaline β-elimination is a typical chemical deglycosylation, which converts a serine residue to dehydroalanine under non-reducing conditions. When aqueous ammonia is used as alkali, the transient dehydroalanine residues generated by β-elimination are instantly modified by a Michael-type addition reaction, yielding 2,3-diaminopropionic acid (Rademaker et al. 1998) . The net mass shift of these . Unsaturated disaccharide analyses of GAG derived from salmon nasal cartilage EPY. GAG chains were digested by chondroitinase ABC (A), AC-II (B) or B (C). Obtained disaccharides were resolved by cation-exchange HPLC on a Polyamine II column and monitored by measuring absorbance at 232 nm. The elution position determined using authentic standards of disaccharides are indicated.
A novel type of large leucine-rich proteoglycan reactions (delta mass = −1) can then be detected by mass spectrometry as corresponding to a GAG-modified serine residue. After β-elimination by aqueous ammonia, protease digestion and MS analysis, the GAG-modified serine residues at many sites can be determined. The single GAG-modified site in bovine decorin is located near its N-terminus (Ser-34, accession ID: NP_776331; Mann et al. 1990 ). The peptide sequence [DEAS GIGPEE; the nucleotide sequence reported in this paper has been submitted to DDBJ with accession number AB762418; the raw sequence data from the next-generation sequence analysis have been submitted to DDBJ DRAwith accession number DRA001005] containing the GAG-modified Ser-34 was matched with 95% confidence level and a Δmass of −0.0014 between precursor and theoretical molecular mass by ProteinPilot. The MS/MS spectrum of the peptide containing the modified Ser-34 showed a mass shift of 1 corresponding to the conversion of serine to 2,3-diaminopropionic acid residue in the b or y fragment ion series (Figure 8 ). This allowed unambiguous identification of the GAG-modified peptide. Alkaline release with aqueous ammonia provided a clear distinction between previously glycosylated Ser-34 and non-modified serine residues in bovine decorin. The GAG-modified serine in bovine decorin was successfully identified as a positive control.
Oncorhynchus keta EPY has 55 possible GAG-modified sites in the N-terminal region, based on the Ser-Gly and/or Gly-Ser dipeptides in the translated cDNA sequence (Figure 1 ). Modified serine residues in EPY from salmon nasal cartilage were identified using the MS-based method outlined above. A peptide containing Ser-100 and Ser-103 in EPY was identified as a GAG-modified peptide with a high degree of confidence (>95). Figure 8 shows an MS/MS spectrum of the peptide containing the modified serine residues. A mass shift of 1 corresponding to the conversion of serine to 2,3-diaminopropionic acid in a b 2+ fragment ion series was observed. The peptide containing nonmodified serine residues was not detected with a reasonable signal level. Most of the other peptides containing Ser-Gly and/ or Gly-Ser were predicted to be modified by GAG with a low confidence level (<50, Supplementary data, Figure S2 ).
Discussion
A global analysis of salmon nasal cartilage using nano-LC/MS/ MS and next-generation DNA sequencing were performed to analyze the structure of proteoglycans. Proteomic analyses of cartilage proteins from mice have been reported (Belluoccio et al. 2006; Wilson et al. , 2009 ). However, proteoglycans substituted by multiple large GAG chains have not been detected by two-dimensional electrophoresis followed by LC-MS/MS due to the heterogeneity of the GAG components. We have previously shown that the major proteoglycan in salmon nasal cartilage is aggrecan by nano-LC/MS/MS analysis (Kakizaki et al. 2011) . In this technique, the aggregate of the cartilage was solubilized using a chaotropic agent, and proteoglycans were subsequently extracted. The proteoglycan fraction was then digested with trypsin, and the liberated tryptic peptides were fractionated by gel-filtration to remove the GAGs. The nano-LC/MS/MS analysis of the peptide fraction made it feasible to identify proteoglycans substituted by complex GAG chains. In this study, we used TripleTOF 5600 with high-speed data acquisition, which enabled comprehensive qualitative measurements to be performed. Using this novel approach, we identified the minor proteoglycans in salmon nasal cartilage.
SLRPs (decorin, biglycan, EPY and prolargin) and a basement membrane proteoglycan ( perlecan) were newly identified in addition to aggrecan (Table I) . When the amino acid sequence such as aggrecan from O. keta (chum salmon) is known, the accuracy of protein identification was high. However, identification scores were lower for other proteoglycans. Although the amino acid sequences of the core protein of proteoglycans from salmon are unavailable, candidates were identified by comparison to D. rerio proteins. These results indicate that the protein identification by using nano-LC/MS/MS and Mascot search is applicable to the identification of proteoglycans from O. keta, which is a non-model organism. Fourteen proteoglycans were identified as a result of the analysis of salmon nasal cartilage at the mRNA and the protein level, and 12 of them (biglycan, ChS proteoglycan 4, decorin, fibromodulin 1b, glypican 4, leprecan 1, lumican, mimecan, perlecan, podocan, prolargin and syndecan 2) were newly identified in this study. These findings are invaluable for analyzing the structure of proteoglycans and the molecular network in salmon nasal cartilage. Indeed, we found that EPY had a novel domain containing many potential GAG-modified sites.
Interestingly, EPY had a unique domain of 384 amino acids in between the signal peptide and the cysteine cluster (Figure 1 ). These amino acids contained a large proportion of Ser-Gly and/or Gly-Ser dipeptides (55 sites). The amino acid sequence of this domain was not detected by nano-LC/MS/MS analysis. Hence, this domain was considered to be entirely modified, i.e. the Ser-Gly and/or Gly-Ser dipeptides were recognized to be substituted by GAG. The Ser-Gly-and/or Gly-Ser-rich domain resembling O. keta EPY is found in the ChS domain of aggrecan from O. keta (Kakizaki et al. 2011) . Although the ChS domain of aggrecan displays low sequence similarity with the GAG domain of EPY, they share a comparable glycine and serine content. EPY had a larger proportion of GAG-modified sites in the GAG domain (55 sites per 384 amino acids) than the ChS domain of O. keta aggrecan (49 sites per 419 amino acids). The Ser-Gly-and/or Gly-Ser-rich domain resembling O. keta EPY is also found in a partial sequence of an unnamed protein product from Tetraodon nigroviridis (accession ID: CAG01882). In zebrafish EPY, the long isoform (dspg3l-l) was reported to have the insertion resembling collagen repeat sequences found in many types of collagens (Zhou et al. 2006) . Unlike the zebrafish EPY long isoform, the GAG domain sequence of EPY from salmon nasal cartilage did not contain a proline residue. No expressed exon encoding the ChS chain-modified domain has been reported. Indeed, this applies not only to mammalian EPY genes (Deere et al. 1996 (Deere et al. , 1999 Kurita et al. 1996; Iwata et al. 1998 ) but also to any proteoglycans including leucine-rich repeats (LRRs; McEwan et al. 2006) .
SLRPs have one (decorin) or two (biglycan and EPY) GAG chains that can be either DS or ChS (Choi et al. 1989; Mann et al. 1990; Kurita et al. 1996) . The corneal proteoglycans such as lumican, fibromodulin and keratocan belong to the SLRP family and are substituted by keratan sulfate Heinegård 1975, 1978; Oldberg et al. 1989; Corpuz et al. 1996) . GAG from salmon nasal cartilage EPY was composed of ChS as a major component (Figure 7) . Neither a keratan sulfate nor N-glycan is considered to be N-linked to Asn of an Asn-Xaa-(Ser/Thr) motif in salmon nasal EPY, because Asn-569, the only potential N-glycosylation site in EPY, was not identified as being modified by nano-LC/MS/MS (Figure 1) . The average molecular weight of GAG from salmon nasal cartilage EPY was estimated to be 3.0 × 10 4 ( Figure 5 ), which corresponds to 60 disaccharide repeating units per chain. ChS/DS chains of EPY, decorin and biglycan from bovine fetal epiphyseal cartilage has a molecular weight of 2. , respectively (Johnson et al. 1997) . Although the molecular weight standard is different in this study, the molecular weight of GAG from salmon nasal cartilage EPY is comparable with those of the ChS/DS chains in the SLRPs.
We applied an analytical method for the discrimination of a GAG-modified serine residue to EPY from salmon nasal cartilage. The GAG-modified serine residues in EPY were identified to be Ser-100 and Ser-103 ( Figure 8B ). The other peptides containing Ser-Gly and/or Gly-Ser dipeptides were identified with low confidence (<50, Supplementary data, Figure S2 ). It is assumed that the low confidence of the identification of the modified serine is due to both the heterogeneous substitution of all GAG-modified sites and uncertainty of analyzing a peptide with heterogeneously substituted multiple glycosylation sites. The peptide fragments produced by V8 protease include heterogeneous and multiple modified serine residues, which are irrelevant for MS/MS analysis due to the trivalent and higher charged ions. The low confidence of the identification also indicates that the peptide includes multiple modified serine residues. So, all the putative GAG-modified sites in EPY are estimated to be heterogeneously substituted by GAG chains. EPY has a GAG domain containing 55 potential GAG-modified sites. The molecular weight of EPY including the core protein (predicted molecular weight of 59,347) and GAG (average molecular weight of 3.0 × 10 4 ) is estimated to be less than 2 × 10 6 . Gel-filtration HPLC of EPY using an OHpak SB-805HQ column did not show a distinct peak (data not shown). This may be due to a wide range of molecular weight of EPY possessing GAG chains varying in number, length and degree of sulfation. Though the estimation of molecular weight using an OHpak SB-805HQ column had failed, the average molecular weight of EPY could be estimated. The core protein abundance of EPY was determined by the Bradford assay. The uronic acid content of GAG was 2.7 mg per 1 mg of core protein. GAG from salmon nasal cartilage EPY was ChS which was composed of a linkage region (-glucuronosyl-galactosyl-galactosyl-xylosyl-) and repetitive disaccharides of glucuronic acid and sulfated N-acetylgalactosamine. The prcentage of sulfation of N-acetylgalactosamine was determined by analysis of unsaturated disaccharides (58.0% Ch6S, 26.5% Ch4S and 15.3% non-sulfated chondroitin). Consequently, the GAG content of purified EPY was calculated to be 6.7 mg per 1 mg of core protein. The average molecular weight of GAG was 3.0 × 10 4 . Therefore, EPY is estimated to include 13 mol of GAG chains per 1 mol of core protein, and the molecular weight is 4.6 × 10 5 on average. Mammalian SLRPs have a leucine-rich core protein of molecular weight 3.8 × 10 4 and one (decorin) or two (biglycan) GAG chains that can be either DS or ChS (Choi et al. 1989; Fisher et al. 1989; Mann et al. 1990) . Although SLRPs in salmon nasal cartilage have not yet been characterized, EPY is predicted to be considerably larger than SLRPs, such as decorin and biglycan. Aggrecan from salmon nasal cartilage is characterized as a core protein of 1324 amino acids (predicted molecular weight of 143,276) and 46 serine residues modified by GAG (Kakizaki et al. 2011) . Mammalian aggrecan is a large proteoglycan possessing a core protein of molecular weight 2.1 × 10 5 -2.5 × 10 5 and 100-150 GAG chains (Hascall and Sajdera 1970; Doege et al. 1987 Doege et al. , 1991 Kiani et al. 2002) . The molecular weight of EPY from salmon nasal cartilage is considered to be lower than aggrecan.
The expression level of EPY mRNA in salmon nasal cartilage is estimated to be higher than that of aggrecan. Specifically, the counts of cDNA sequences matched to EPY and aggrecan were 311 and 161 per 39,585 reads in the next-generation sequencing, respectively. But it is considered that the ratio of EPY is lower than that of aggrecan at the protein level. The relative amount of EPY in the extract of salmon nasal cartilage was detected by dot blot analysis (data not shown). The content of EPY was calculated by a standard curve using the purified EPY.
A novel type of large leucine-rich proteoglycan
The total weight of EPY in the extract was brought about by the average molecular weight mentioned above. Accordingly, the extract of salmon nasal cartilage was calculated to contain no more than 10% EPY (ratio by weight). The amount of EPY, however, is enough to play a structural role in salmon nasal cartilage. Some proteoglycans, such as aggrecan, decorin and biglycan, are expressed in cartilage and are thought to play important roles in chondrogenesis and cartilage formation (Knudson and Knudson 2001) . Aggrecan interacts with strands of hyaluronan (HA) through the HA-binding domain to form a very high molecular weight aggregate (Hascall 1977) . SLRPs bind to collagens through LRRs and seem to be involved in many aspects of collagen fibril formation (Hocking et al. 1998; Iozzo 1999; McEwan et al. 2006) . Unlike aggrecan, EPY does not have a HA-binding domain in the deduced amino acid sequence (Figure 1 ), but has a GAG-modified domain resembling aggrecan that is substituted by multiple GAG chains. Moreover, EPY has LRRs homologous to SLRPs, suggesting the two molecules share a similar function. The role of EPY in the assembly of salmon nasal cartilage remains to be investigated. In this way, EPY is distinguished from aggrecan and SLRPs. Hence, we propose a novel category of a large leucine-rich proteoglycan for EPY from salmon nasal cartilage.
Materials and methods
Materials
Frozen salmon nasal cartilage slices for protein analysis were purchased from Kakuhiro (Hirosaki, Japan) and fresh male salmon for cDNA analysis was from the ocean of Fukaura, Aomori, Japan. Trypsin from porcine pancreas (proteomics grade, dimethylated) was from Sigma-Aldrich (St Louis, MO). A goat polyclonal antibody (anti-DSPG3 antibody) against the LRR domain of EPY as an epitope was from Santa Cruz Biotechnology. The rabbit polyclonal antibody (anti-aggrecan G3 antibody) against the carbohydrate recognition domain of aggrecan (amino acid residues 2276-2293 in human aggrecan) was from Affinity BioReagents (Golden, CO). Peroxidase-conjugated rabbit anti-goat immunoglobulin and peroxidase-conjugated goat anti-rabbit immunoglobulin were from Dako Japan (Tokyo, Japan). GAG standards for cellulose acetate membrane electrophoresis including Ch4S, Ch6S, DS, HS, heparin (Hep) and HA were purchased from Seikagaku Kogyo (Tokyo, Japan). Chondroitinase AC-II (from Arthrobacter aurescens), chondroitinase B (from Flavobacterium heparinum), chondroitinase ABC (from Proteus vulgaris) and six unsaturated disaccharide standards derived from ChS, 2-acetamido-2-deoxy-
, were also purchased from Seikagaku Kogyo Co. Hep (from porcine intestinal mucosa; average molecular weight 1.9 × 10 4 ) and cellulase from A. niger were from Sigma-Aldrich. V8 protease from Staphylococcus aureus were from Wako Pure Chemicals (Osaka, Japan). The PCR cloning vector pCR2.1 was from Invitrogen (NV Leek, Holland). All other chemicals were the analytical grade.
Nano-LC/MS/MS
Proteoglycan fraction extracted from salmon nasal cartilage and fractionated by DEAE-Sephacel™ anion-exchange column chromatography was prepared as described previously (Kakizaki et al. 2011) . One milligram of the proteoglycan was reducedalkylated following the conventional method (Anfinsen and Haber 1961) . The sample was dissolved in 180 μL of 6 M guanidine-HCl containing 0.1 M dithiothreitol. The vial was allowed to stand in darkness with nitrogen gas for 2 h at 42°C, and then 40 μL of 0.9 M iodoacetamide was added. After 3 h at room temperature, 1 mL of ethanol and 40 μL of 5 M ammonium acetate were added to the mixture. The sample was precipitated by centrifugation for 10 min at 15,000 × g. Proteoglycans were digested with trypsin and the digested products were analyzed by HPLC (Elite LaChrom, Hitachi, Tokyo, Japan) equipped with an auto-sampler (L-2200), a Shodex OH pak SB-803HQ column (8.0 × 300 mm, Shodex, Showa Denko K. K., Kawasaki, Japan), a column oven (L-2350), a HPLC pump (L-2130) and a UV-Vis Detector module (L-2420). The trypsin-digested peptide fragments were eluted with 4 M guanidine-HCl in 20 mM sodium phosphate buffer (pH 6.0) at 0.5 mL/min. The UV absorbance of the eluate was monitored at 215 nm. The fractions that contained oligopeptides were pooled and desalted using ZipTip C18 (Millipore, Billerica, MA). The samples were applied to a nano-LC system, DiNa-2A (KYA Technologies, Tokyo, Japan) with a C18 separation column (HiQ Sil C18-3, 0.8 mm × 3 mm, KYATechnologies) followed by analysis using a quadrupole time-of-flight tandem mass spectrometer (Triple TOF 5600, AB Sciex, Tokyo, Japan). The acquired MS/MS spectra were submitted to ProteinPilot software 4.0 (AB Sciex) and analyzed against the non-redundant NCBI database with a taxonomy restriction confined to Actinopterygii proteins. ProteinPilot confidence score >1.3 (i.e. 95% confidence level; false-positive identification probability of 5%) was employed for the identification of protein candidates.
cDNA library construction and 454 sequencing Total RNAs were extracted from fresh salmon nasal cartilage using RNeasy Mini Kit (Qiagen, Tokyo, Japan). Total RNA purity and degradation were checked on 0.7% agarose gels before proceeding. The construction of a cDNA library from the total RNA and the pyrosequencing was performed by Dragon Genomics Center, Takara Bio (Otsu, Japan) using the Genome Sequencer FLX System. The cDNA library was constructed according to the manufacturer's protocols using GS FLX Titanium Rapid Library Preparation Kit (Roche Applied Science, Mannheim, Germany). PolyA+ RNA was purified from 100 µg total RNA using Sera Mag Magnetic Oligo (dT) microparticles (Seradyn, Indianapolis, IN) and subjected to simultaneous fragmentation. Double-stranded DNA was generated and subjected to adaptor ligation. The DNA was subsequently cleaned using the Agencourt Ampure XP system (Beckman Coulter, Brea, CA). The cDNA library was amplified onto DNA capture beads by emulsion PCR. Collected beads were placed on the picotitre plate. The DNA fragments were Sequence assembly and annotation of unique sequences The Contig Assembly Program (CAP3; Huang 1992; Huang and Madan 1999) was used to cluster sequences into contigs and singletons for the assembly of relatively long sequences and to remove redundant short reads. An overlap length cutoff of 30 nucleotides and an identity threshold of 75% were employed. Plausible functions for the established contigs were designated by gene homology based on BLAST search.
cDNA synthesis and cloning of EPY gene Total RNAs were extracted from fresh salmon nasal cartilage using RNeasy Mini Kit (Qiagen). The total RNAs were primed with 100 ng of the oligo-(dT) primer. First-strand DNA synthesis was performed with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) and ribonuclease H (Invitrogen, Carlsbad, CA). The following primers were designed based on the contig sequenced by the next-generation sequencing and were used for reverse transcription-PCR to amplify the EPY gene: 5′-TGAGCAACCTC TCACCATTGGC-3′ (forward) and 5′-GGATCTGTCCAG TAGGTAAGTGTGTGTATGG-3′ (reverse). PCR was carried out in the 50 µL of PCR mixture containing 25 mM 3-[Tris (hydroxymethyl)methylamino]-1-propanesulfonic ( pH 9.3), 50 mM KCl, 2 mM MgCl 2 , 0.1 mM dithiothreitol, 200 µM of each deoxynucleoside triphosphate, 4 µM each primer, 500 ng of first-strand DNA and 2.5 units of Taq-DNA polymerase (TaKaRa Ex Taq). The PCR cycle conditions were 94°C for 2 min followed by 30 cycles of 94°C for 1 min, 58°C for 30 s and 72°C for 2 min for the amplification of EPY gene. A 2 µL aliquot of each PCR mixture was separated on a 1.5% agarose gel, and the bands were visualized with ethidium bromide staining and gel-purified. The pCR2.1 vector including EPY gene was constructed by inserting the PCR product (2 kb) into plasmid pCR2.1, using an Original TA Cloning Kit (Invitrogen).
DNA sequencing
The cloned EPY genes were subjected to cycle sequencing with the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) according to the manufacturer's instructions. Specific primers for EPY gene sequencing were designed based on the nucleotide sequences encoding the EPY gene from salmon nasal cartilage mRNA analyzed by the nextgeneration sequencing. Reaction products were separated by capillary electrophoresis on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). Raw sequencing data were analyzed by DNA Sequencing Analysis software v5.3.1 (Applied Biosystems).
Purification of salmon nasal EPY Proteoglycan was extracted from salmon nasal cartilage slices (10 g) according to the published procedure (Malawista and Schubert 1958; Hascall and Sajdera 1969; Sajdera and Hascall 1969 ) using 4 M guanidine-HCl, 50 mM sodium acetate buffer ( pH 6.0) containing 10 mM ethylenediaminetetraacetic acid (EDTA) 2Na, 5 mM benzamidine hydrochloride, 10 mM N-ethylmaleimide, 1 mM phenylmethylsulfonyl fluoride (PMSF), after the delipidation of cartilage slices by the method of Folch et al. (1957) . The proteoglycan extract (50 mg dry weight) was then purified by the following protocol. The proteoglycan extract was dissolved in 7 M urea, 50 mM Tris-HCl buffer ( pH 7.4) containing proteinase inhibitor cocktail and applied to a DEAE-Sephacel™ anion-exchange column (2.7 × 30 cm, GE Healthcare Japan, Tokyo, Japan) at a flow rate of 30 mL/h. The bound proteoglycans were eluted with a linear gradient of 0-1.0 M NaCl. Fractions determined to be positive both for uronic acid and for protein, and whose elution position corresponded to around 0.5 M NaCl, were regarded as proteoglycans. These fractions were pooled and then concentrated by ultrafiltration using Amicon Ultra (Millipore). The proteoglycans were fractionated by gel filtration chromatography on a Sepharose CL-4B column (1.8 × 110 cm, GE Healthcare Japan) equilibrated with 4 M guanidine-HCl in 50 mM sodium acetate buffer ( pH 6.0). The fractions were tested by dot blot analysis using anti-DSPG3 and anti-aggrecan G3 domain antibody. The fractions containing EPY were pooled, and the solvent was replaced by 100 mM sodium acetate buffer ( pH 5.0) containing 2 M guanidine-HCl using Amicon Ultra. EPY was isolated on Octyl-Sepharose (20 × 100 mm) equilibrated with 100 mM sodium acetate buffer ( pH 5.0) containing 2 M guanidine-HCl using a linear gradient of 2-6 M guanidine-HCl. The purified EPY was concentrated by ultrafiltration and frozen at −20°C. Percent yield of the EPY purification was calculated as total weight of uronic acid in purified EPY fraction per that in guanidine − extract of salmon nasal cartilage. Uronic acid content of fractions was determined by a specific color reaction of hexuronic acids according to the carbazole-sulfuric acid method (Bitter and Muir 1962) . Protein content of fractions was determined by the method of Bradford (Bradford 1976) or by monitoring the UV absorbance at 280 nm. Relative amount of EPY in a fraction was estimated by dot blot analysis. An aliquot was blotted onto a polyvinylidene difluoride membrane (Immobilon P, Millipore) previously pre-wetted in methanol (15 s), deionized water (2 min) and dot blot buffer 20 mM Tris-HCl buffer ( pH 7.5) containing 0.15 M NaCl and 0.05% Tween-20 (5 min). The membrane was blocked with 3% non-fat dry milk in Tris-buffered saline containing 0.05% Tween-20 and incubated with the appropriate primary antibody (anti-DSPG3). Secondary antibody was peroxidase-conjugated anti-goat IgG. Immunoreactive protein was detected by using an enhanced chemiluminescence reagent (GE Healthcare Japan).
Preparation of core protein
The purified EPY was digested by chondroitinase ABC in 0.1 M Tris-HCl buffer ( pH 8.0) containing 0.1 M sodium acetate (Yamagata et al. 1968) . The solution was loaded onto a PD-10 gel-filtration column (GE Healthcare Japan) pre-equilibrated with 50 mM sodium phosphate buffer ( pH 6.0). The EPY core protein was pooled and stored at −20°C.
Preparation of GAG chain
The concentrated EPY solution was digested by actinase E (Kaken Pharmaceutical, Tokyo, Japan) in 0.1 M Tris-HCl A novel type of large leucine-rich proteoglycan buffer ( pH 8.0) containing 10 mM CaCl 2 at 50°C for 24 h, resulting in a peptidoglycan form. The peptidoglycan was precipitated with a 4-fold volume of NaCl-saturated ethanol. The peptidoglycan was digested by cellulase in 0.1 M sodium acetate buffer ( pH 5.0) at 50°C for 16 h, i.e. endo-β-xylosidase activity of cellulase liberates the GAG chain (Takagaki et al. 2002) . The enzyme was inactivated by boiling for 5 min. After centrifugation, the supernatant was recovered and precipitated with a 4-fold volume of NaCl-saturated ethanol to obtain a fraction containing the GAG chains. The precipitate was dissolved in 50 mM Tris-HCl buffer ( pH 7.4) containing 7 M urea and loaded onto a DEAE-Sephacel™ anion-exchange column (10 × 100 mm) pre-equilibrated with the same buffer. The bound GAGs were subsequently eluted with a linear gradient of 0-2.0 M NaCl. The GAG fractions were pooled and precipitated with a 4-fold volume of NaCl-saturated ethanol. The precipitate was dissolved in water and stored at −20°C.
Estimation of the molecular weight of GAG An aliquot of EPY GAG (10 µg) was loaded onto a OHpak SB-805HQ column (8 × 300 mm, Shodex, Showa Denko K. K., Tokyo, Japan) using a HPLC system (Hitachi). We calibrated a standard curve of molecular weight as a function of the retention time of the standards on the column. The column was eluted with 0.2 M NaCl at a flow rate of 0.5 mL/min. The GAG was detected by absorbance at 215 nm.
Enzymatic digestion of GAG GAGs (10 µg) were incubated in 120 µL of chondroitinase ABC (5 mU) dissolved in 0.1 M Tris-HCI buffer ( pH 8.0) including 0.01% bovine serum albumin (BSA) and 30 mM sodium acetate at 37°C for 72 h. GAGs (10 µg) were also incubated under the same conditions in either 120 µL of chondroitinase AC-II (5 mU) dissolved in 0.1 M sodium acetate buffer ( pH 6.0) including 0.01% BSA or 120 µL of chondroitinase B (5 mU) dissolved in 0.1 M Tris-HCI buffer ( pH 8.0) including 0.01% BSA and 30 mM sodium acetate. After the inactivation of the enzyme (boiling for 2 min), the reactants were filtered (0.45 μm; Microspin centrifuge filters).
Analysis of unsaturated disaccharides
Unsaturated disaccharides were separated by HPLC (Hitachi) on a Polyamine II column (4.6 × 250 mm; YMC, Tokyo, Japan) at 40°C using a flow rate of 1 mL/min. The unsaturated disaccharides were eluted with a linear gradient of 16-246 mM NaH 2 PO 4 for 60 min and detected by their absorbance at 232 nm. The elution position of unsaturated disaccharides was determined using a set of standards. Relative abundance of different disaccharides was calculated by the automatic integration of the respective peak areas. Identification and quantification of the resulting disaccharides was achieved by comparison with ChS-derived authentic unsaturated disaccharides: ΔDi-0S, ΔDi-6S, ΔDi-4S, ΔDi-diS D , ΔDi-diS E and ΔDi-triS.
Cellulose acetate membrane electrophoresis One microliter of the GAG solution, containing 1 μg of uronic acid, was placed at the origin (10 mm from the cathode side) of a cellulose acetate membrane (85 mm width, Separax, Jookoo Co., Tokyo). Electrophoresis was carried out in 100 mM pyridine/470 mM formic acid ( pH 3.0) at 8.5 mA constant current (20 min, room temperature; Mathews 1961). After electrophoresis, the cellulose acetate membrane was stained with 0.1% alcian blue (w/v), in 50 mM sodium acetate buffer ( pH 5.8) containing 50% ethanol (v/v) and 50 mM MgCl 2 for 10 min and washed with the same solution minus alcian blue for 20 min.
Identification of GAG-modified serine in EPY Ten micrograms of the purified EPY was reduced alkylated following the conventional method (Anfinsen and Haber 1961) . The reduced-alkylated EPY was digested with chondroitinase ABC in 0.1 M Tris-HCl buffer ( pH 8.0) containing 0.1 M sodium acetate and then precipitated using 80% acetone. The remaining linkage regions of GAG were eliminated from serine residues by ammonia treatment. The resulting dehydroalanine was converted to 2,3-diaminopropionic acid residue via conjugate addition (Rademaker et al. 1998) .
The acetone precipitate was dissolved in 300 μL of 25% NH 4 OH and incubated at 45°C for 6 h. The reaction was subsequently stopped by removing the reagent under reduced pressure (vacuum centrifuge). Fragmentation of the protein was performed with V8 protease in 0.1 M sodium phosphate buffer (pH 7.8) at 25°C for 24 h, and the digested products were desalted using ZipTip C18 (Millipore). The sample was analyzed by nano-LC/MS/MS as described in nano-LC/MS/MS section. The acquired MS/MS spectra were submitted to Protein Pilot software 4.0 (AB Sciex) and searched with a special factor to identify peptides containing 2,3-diaminopropionic acid residues as serine residues that were modified with GAG. Decorin (from bovine articular cartilage, Sigma-Aldrich), which has a single GAG covalently bound to Ser-34, was used as a positive control for the identification of the GAG-modified serine residues.
Supplementary data
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